Details of the Drug

General Information of Drug (ID: )

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw)
  Logarithm of the Partition Coefficient (xlogp)
  Rotatable Bond Count (rotbonds)
  Hydrogen Bond Donor Count (hbonddonor)
  Hydrogen Bond Acceptor Count (hbondacc)
• ADMET Property:
  Bioavailability: The bioavailability of drug is 30% [1]
  Clearance: The total clearance of drug is 374 mL/min [2]
  Elimination: 84.7% of drug is eliminated in the feces and 5.4% is eliminated in the urine [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 155 hours [2]
  Metabolism: The drug is metabolized via plasma [2]
  Vd: The volume of distribution (Vd) of drug is 1110 L [1]

References

• [1] Graefe-Mody U, Retlich S, Friedrich C: Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012 Jul 1;51(7):411-27. doi: 10.2165/11630900-000000000-00000.
• [2] The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010 Apr;38(4):667-78. doi: 10.1124/dmd.109.031476. Epub 2010 Jan 19.